"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves apalutamide (Erleada) for patients with mCSPC

20 Sep 2019 11:22 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved apalutamide (Erleada; Janssen) for patients with metastatic castration-sensitive prostate cancer (mCSPC). Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software